Iberiabank Corp purchased a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 433 shares of the biopharmaceutical company’s stock, valued at approximately $270,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. United Capital Financial Advisers LLC boosted its stake in Regeneron Pharmaceuticals by 35.4% during the 1st quarter. United Capital Financial Advisers LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $586,000 after purchasing an additional 314 shares during the period. Mutual of America Capital Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 1.4% during the first quarter. Mutual of America Capital Management LLC now owns 10,881 shares of the biopharmaceutical company’s stock worth $5,313,000 after buying an additional 148 shares during the period. Anderson Fisher LLC grew its holdings in Regeneron Pharmaceuticals by 116.7% in the 1st quarter. Anderson Fisher LLC now owns 117 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 63 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in Regeneron Pharmaceuticals by 4,727.4% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 23,220 shares of the biopharmaceutical company’s stock valued at $11,338,000 after acquiring an additional 22,739 shares during the period. Finally, Valeo Financial Advisors LLC increased its position in Regeneron Pharmaceuticals by 5.2% in the 2nd quarter. Valeo Financial Advisors LLC now owns 447 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 22 shares during the period. 68.07% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have recently issued reports on the company. Credit Suisse Group increased their price target on Regeneron Pharmaceuticals from $700.00 to $716.00 and gave the stock an “outperform” rating in a research note on Monday, July 20th. Goldman Sachs Group increased their target price on shares of Regeneron Pharmaceuticals from $636.00 to $700.00 and gave the company a “conviction-buy” rating in a research report on Wednesday, May 6th. Cowen reissued a “hold” rating and set a $584.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, June 2nd. SVB Leerink upped their price target on shares of Regeneron Pharmaceuticals from $622.00 to $625.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 27th. Finally, Robert W. Baird increased their price objective on shares of Regeneron Pharmaceuticals from $487.00 to $510.00 and gave the company a “neutral” rating in a report on Wednesday, May 6th. Thirteen equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $568.50.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $6.60 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $6.13 by $0.47. Regeneron Pharmaceuticals had a return on equity of 24.94% and a net margin of 28.56%. The company had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.81 billion. During the same period last year, the business posted $4.45 earnings per share. The firm’s revenue was up 6.8% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals Inc will post 23.48 earnings per share for the current year.
In other news, EVP Andrew J. Murphy sold 2,380 shares of the business’s stock in a transaction that occurred on Tuesday, July 14th. The stock was sold at an average price of $633.48, for a total transaction of $1,507,682.40. Following the sale, the executive vice president now directly owns 44,067 shares in the company, valued at $27,915,563.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Christopher R. Fenimore sold 3,556 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $590.89, for a total value of $2,101,204.84. Following the completion of the transaction, the vice president now owns 20,323 shares of the company’s stock, valued at $12,008,657.47. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 210,582 shares of company stock worth $122,348,282. Insiders own 11.84% of the company’s stock.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.